Biosignal Ltd (ASX: BOS) has engaged US company Bioduro Inc to further develop two different classes of therapeutic compounds based on Biosignal's novel technology. Biosignal's therapeutic target markets are respiratory infections and urinary tract infections. BioDuro is a leading life science outsourcing services company with particular strengths in discovery and pre-clinical chemistry. [click
NEW YORK----The UBS Global Life Sciences Conference opens today at the Grand Hyatt in New York City and runs through Thursday, September 28. The Conference will feature presentations by more than 340 public and private companies representing biotechnology, medical device manufacturers, pharmaceuticals and specialty pharmaceutical.
NORWALK, Conn.----Sept. 21, 2006--With just a few days left until the opening of the 2006 Pharmaceutical Strategic Alliances Conference, an exciting agenda is set and all the major players in the biopharmaceuticals industry are planning to attend.
It is the opinion of many biotech executives that the best time to raise money is when you don't need it. With a nine-digit figure in the bank, it seems as though that is just what Vertex Pharmaceuticals Inc. did late last week.